Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.

Bull Case How might positive itepekimab data impact Regeneron’s valuation? Positive data from the itepekimab COPD trials could significantly boost Regeneron’s prospects and stock valuation.

Bernstein SocGen lowered Regeneron’s price target from $896 to $750 while maintaining an Outperform rating, after mixed Phase 3 trial results for itepekimab in COPD. The trial results led to a notable ...

Meanwhile, RBC Capital Markets downgraded Regeneron’s stock rating from Outperform to Sector Perform, citing disappointing results from the clinical trials of the drug candidate itepekimab. Despite ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...